Outcomes for dexamethasone-treated patients and matched controls.

Outcomes and crude odds ratios (95% CI) comparing dexamethasone recipients to PS-matched non-recipients in N3C hospitalized COVID-19 patients. Non-recipients of remdesivir are matched 3:1 (non-dexamethasone to dexamethasone), while remdesivir recipients are matched 1:1.